. 2015 Jan 11;262(3):752–759. doi: 10.1007/s00415-014-7618-y

Table 2.

Sequential changes in MMT sum scores after intravenous immunoglobulin administration

	a. Baseline^a	b. 2 weeks	c. 4 weeks	d. 6 weeks	e. 8 weeks	p values*
	a. Baseline^a	b. 2 weeks	c. 4 weeks	d. 6 weeks	e. 8 weeks	b–a	c–a	d–a	e–a
MMT sum scores and the change in MMT sum scores
Group A (n = 8)	110.00 ± 12.56	118.13 ± 11.15	122.75 ± 9.99	123.81 ± 10.16	124.50 ± 9.07	0.046	0.015	0.016	0.011
Group A (n = 8)	–	8.13 ± 9.49	12.75 ± 11.29	13.81 ± 12.44	14.50 ± 11.87	0.046	0.015	0.016	0.011
Group B (n = 8)	117.19 ± 11.50	123.00 ± 13.20	128.06 ± 13.05	127.81 ± 11.40	128.63 ± 11.21	0.022	0.019	0.014	0.006
Group B (n = 8)	–	5.81 ± 5.62	10.88 ± 10.12	10.63 ± 9.24	11.44 ± 8.36	0.022	0.019	0.014	0.006
Group C (n = 7)	112.86 ± 23.83	120.36 ± 12.49	123.50 ± 10.22	124.36 ± 9.99	128.07 ± 8.01	0.214	0.151	0.125	0.059
Group C (n = 7)	–	7.50 ± 14.26	10.64 ± 17.12	11.50 ± 17.09	15.21 ± 17.29	0.214	0.151	0.125	0.059
All patients (n = 23)	113.37 ± 16.02	120.50 ± 11.91	124.83 ± 10.97	125.37 ± 10.23	127.02 ± 9.34	0.002	<0.001	<0.001	<0.001
All patients (n = 23)	–	7.13 ± 9.76^b	11.46 ± 12.41	12.00 ± 12.57	13.65 ± 12.30	0.002	<0.001	<0.001	<0.001

MMT manual muscle testing

* Paired t test for change from baseline

^aBaseline scores were those immediately before intravenous immunoglobulin administration

^bPrimary endpoint